Chiesi
Chiesi expands La Chaussée-Saint-Victor site to manufacture next-gen inhalers
November 10, 2025Manufacturing and Production Chiesi, Metered Dose Inhalers, Site Expansion, respiratory diseases
Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its manufacturing and industrial site in …
NICE recommends treatment for rare genetic eye disorder
August 11, 2025Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …
Great Place To Work® and Fortune Name Chiesi Group No. 23in 2024 World’s Best Workplaces™ List
November 19, 2024Chiesi, Corporate, best workplace
Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best …
Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib
May 7, 2024Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration
US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …
New Year, new goals
February 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer Research UK, Chiesi, EMA, FDA, Genetic Alliance, pharma
With the New Year begun in earnest, Pharmafocus speaks to a range of players in pharma and the life sciences …
EMA committee recommends seven therapies from Roche, GSK, MSD and more
January 29, 2018Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …
Chiesi set to acquire Medicine Co cardiovascular assets, say reports
May 9, 2016Sales and Marketing Chiesi, assets, cardiovascular, medicine co
Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …
Chiesi rapped for ABPI code breach
May 7, 2015Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA
Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its …
Chiesi reprimanded again over Fostair drug
March 3, 2015Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA, code, formoterol/beclometason, fostair
Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The …
Chiesi’s stem cell therapy approved in Europe
February 23, 2015Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell
Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …
Chiesi gets first-ever European stem cell nod
December 19, 2014Sales and Marketing Chiese, Chiesi, EMA, Holoclar, LSCD, MHRA, Stem cells, orexigen
Chiesi has received the first approval for an advanced therapy medicinal product containing stem cells for use in Europe. The …
Chiesi publicly reprimanded
December 13, 2013Sales and Marketing ABPI, Chiesi, PMCPA, fostair
Chiesi has had the book thrown at it by the PMCPA and faces the shame of a public reprimand – …
Chiesi snaps up Zymenex
August 29, 2013Sales and Marketing Chiesi, lamazym, rare diseases, zymenex
Chiesi Group is to acquire biopharma company Zymenex Holdings, allowing the Italian firm to enter the rare disease arena for …
PMCPA reprimands Chiesi for multiple breaches
June 18, 2012Sales and Marketing COPD, Chiesi, GSK, PMCPA, code
Chiesi has been publicly reprimanded by the PMCPA part for promoting its asthma drug Fostair off-label. The embarrassing slapdown from …
Chiesi breaks ground on new R&D headquarters in Palma
July 13, 2009Research and Development Chiesi, Europe, Italy
Construction of Chiesi's new 70 million euro centre for research and development has begun in Parma, Italy. The Italian company …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
